213 related articles for article (PubMed ID: 26743240)
21. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
22. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
Forti A; Garcia EG; Yu MB; Jimenez MC; Brodows RG; Oliveira JH
Curr Med Res Opin; 2008 Sep; 24(9):2437-47. PubMed ID: 18662495
[TBL] [Abstract][Full Text] [Related]
24. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
26. [Improved blood sugar control plus weight loss].
Göke B
MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
28. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
30. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
Tokuda M; Katsuno T; Ochi F; Miyakoshi K; Kusunoki Y; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
Endocr J; 2014; 61(4):365-72. PubMed ID: 24452017
[TBL] [Abstract][Full Text] [Related]
31. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR; Klein EJ; Han J; Iqbal N
Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
[TBL] [Abstract][Full Text] [Related]
33. A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
Polster M; Zanutto E; McDonald S; Conner C; Hammer M
J Med Econ; 2010; 13(4):655-61. PubMed ID: 21034377
[TBL] [Abstract][Full Text] [Related]
34. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
35. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
36. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
[TBL] [Abstract][Full Text] [Related]
37. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
Quan H; Zhang H; Wei W; Fang T
J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
[TBL] [Abstract][Full Text] [Related]
38. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
39. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Drucker DJ; Buse JB; Taylor K; Kendall DM; Trautmann M; Zhuang D; Porter L;
Lancet; 2008 Oct; 372(9645):1240-50. PubMed ID: 18782641
[TBL] [Abstract][Full Text] [Related]
40. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
Wu JD; Xu XH; Zhu J; Ding B; Du TX; Gao G; Mao XM; Ye L; Lee KO; Ma JH
Diabetes Technol Ther; 2011 Feb; 13(2):143-8. PubMed ID: 21284481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]